ArticleJAMA cardiology2019
Cardiovascular Risk Factors Associated With Venous Thromboembolism.
Article in JAMA cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 177 papers, 13 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
177 citing papers in PubMed, 13 syntheses or guidelines pooled it, 357 citations in OpenAlex.
- Venous thromboembolism with modern glucose-lowering agents in diabetes: active-comparator evidence beyond placebo-based meta-analyses.Internal and emergency medicine · 2026Pooled it
- A Systematic Review and Meta-analysis of the Efficacy and Safety of Lytic and Non-lytic Early Thrombus Removal Technologies for Iliofemoral Deep Vein Thrombosis.Annals of surgery · 2026Pooled it
- Role of physical activity and sedentary behavior in venous thromboembolism: a systematic review and dose-response meta-analysis.Scientific reports · 2024Pooled it
- The significance of metabolic disease in degenerative cervical myelopathy: a systematic review.Frontiers in neurology · 2024Pooled it
- Plasma levels of coagulation factors VIII and IX and risk of venous thromboembolism: Systematic review and meta-analysis.Thrombosis research · 2023Pooled it
- Blood pressure and risk of venous thromboembolism: a cohort analysis of 5.5 million UK adults and Mendelian randomization studies.Cardiovascular research · 2023Pooled it
- Genome-wide meta-analysis identifies 93 risk loci and enables risk prediction equivalent to monogenic forms of venous thromboembolism.Nature genetics · 2023Pooled it
- Mechanical Thrombectomy for Acute and Subacute Blocked Arteries and Veins in the Lower Limbs: A Health Technology Assessment.Ontario health technology assessment series · 2023Pooled it
- Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials.Cardiovascular research · 2022Pooled it
- Fracture Risks in Patients Treated With Different Oral Anticoagulants: A Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2021Pooled it
- Physical activity and risk of venous thromboembolism: systematic review and meta-analysis of prospective cohort studies.European journal of epidemiology · 2020Pooled it
- Comparison of risk factor associations in UK Biobank against representative, general population based studies with conventional response rates: prospective cohort study and individual participant meta-analysis.BMJ (Clinical research ed.) · 2020Pooled it
- Effectiveness of Neuromuscular Electrical Stimulation in Preventing Venous Thromboembolism: A Meta-Analysis Based on Randomized Controlled Trials.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.Annals of the rheumatic diseases · 2023Trial
- Enhancing venous thromboembolism risk prediction after immunotherapy for lung cancer.iScience · 2026Article
- Venous Thromboembolism and Bleeding Risk in a Population with Obesity Hospitalized for Surgery and Receiving Enoxaparin for Thromboprophylaxis.Obesity surgery · 2026Article
- Pulmonary Embolism-Attributable Mortality in Patients With Heart Failure in the United States, 2010 to 2020.JACC. Advances · 2026Article
- Venous thromboembolic and bleeding risk in population with obesity hospitalized for an acute medical illness receiving enoxaparin for thromboprophylaxis.Research and practice in thrombosis and haemostasis · 2026Article
- Current Approaches to the Management of Acute Surgical and Medical Emergencies: A Structured Narrative Review.Cureus · 2026Review
- Association of triglyceride-glucose related indices with the incidence of venous thromboembolism: a nationwide prospective cohort study based on the UK Biobank.BMC cardiovascular disorders · 2026Article
117 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
75 authors at 20 institutions in 15 countries.
Funding
Abstract
Importance: It is uncertain to what extent established cardiovascular risk factors are associated with venous thromboembolism (VTE). Objective: To estimate the associations of major cardiovascular risk factors with VTE, ie, deep vein thrombosis and pulmonary embolism. Design, Setting, and Participants: This study included individual participant data mostly from essentially population-based cohort studies from the Emerging Risk Factors Collaboration (ERFC; 731 728 participants; 75 cohorts; years of baseline surveys, February 1960 to June 2008; latest date of follow-up, December 2015) and the UK Biobank (421 537 participants; years of baseline surveys, March 2006 to September 2010; latest date of follow-up, February 2016). Participants without cardiovascular disease at baseline were included. Data were analyzed from June 2017 to September 2018. Exposures: A panel of several established cardiovascular risk factors. Main Outcomes and Measures: Hazard ratios (HRs) per 1-SD higher usual risk factor levels (or presence/absence). Incident fatal outcomes in ERFC (VTE, 1041; coronary heart disease [CHD], 25 131) and incident fatal/nonfatal outcomes in UK Biobank (VTE, 2321; CHD, 3385). Hazard ratios were adjusted for age, sex, smoking status, diabetes, and body mass index (BMI). Results: Of the 731 728 participants from the ERFC, 403 396 (55.1%) were female, and the mean (SD) age at the time of the survey was 51.9 (9.0) years; of the 421 537 participants from the UK Biobank, 233 699 (55.4%) were female, and the mean (SD) age at the time of the survey was 56.4 (8.1) years. Risk factors for VTE included older age (ERFC: HR per decade, 2.67; 95% CI, 2.45-2.91; UK Biobank: HR, 1.81; 95% CI, 1.71-1.92), current smoking (ERFC: HR, 1.38; 95% CI, 1.20-1.58; UK Biobank: HR, 1.23; 95% CI, 1.08-1.40), and BMI (ERFC: HR per 1-SD higher BMI, 1.43; 95% CI, 1.35-1.50; UK Biobank: HR, 1.37; 95% CI, 1.32-1.41). For these factors, there were similar HRs for pulmonary embolism and deep vein thrombosis in UK Biobank (except adiposity was more strongly associated with pulmonary embolism) and similar HRs for unprovoked vs provoked VTE. Apart from adiposity, these risk factors were less strongly associated with VTE than CHD. There were inconsistent associations of VTEs with diabetes and blood pressure across ERFC and UK Biobank, and there was limited ability to study lipid and inflammation markers. Conclusions and Relevance: Older age, smoking, and adiposity were consistently associated with higher VTE risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.